New drug combo aims to improve First-Line colorectal cancer treatment
NCT ID NCT07462143
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called RC148 combined with chemotherapy as a first treatment for people with advanced colorectal cancer that cannot be surgically removed. About 80 participants will receive either RC148 plus chemo or the standard bevacizumab plus chemo. The goal is to see if the new combination works better at shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RC148 (a drug) combined with chemotherapy (capecitabine and oxaliplatin)
What this could lead to
If it works, this could offer a new first-line treatment option for people with advanced colorectal cancer that cannot be removed by surgery.
What could go wrong
This is an early-to-mid stage trial with only 80 participants, so results may not apply to everyone. The new drug combination may not be more effective or safer than the current standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL (COLON OR RECTAL) CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiangnan University
RECRUITINGWuxi, Jiangsu, China
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, China
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, China
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanjing, Guangxi, China
-
Jiangsu Cancer Hospital
RECRUITINGNanjing, Jiangsu, China
-
Meizhou People's Hospital
RECRUITINGMeizhou, Guangdong, China
-
People's Hospital of Tianjin
RECRUITINGTianjin, Tianjin Municipality, China
-
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
-
Shanxi Cancer Hospital
RECRUITINGTaiyuan, Shanxi, China
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
-
The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital
RECRUITINGShijiazhuang, Hebei, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
-
The first hospital of Jilin University
RECRUITINGChangchun, Jilin, China
-
Tongji Medical College of Huazhong University of Science &Technology
RECRUITINGWuhan, Hubei, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
-
Yunnan Cancer Hospital
RECRUITINGKunming, Yunnan, China